Navigation Links
Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
Date:5/15/2008

of 2008, assuming successful completion of the ongoing R7128 Phase 1

study, transfer of Pharmasset's IND to Roche, timely progress on agreed

development timelines, completion of all required Phase 2b study

preclinical and clinical preparation activities, manufacture of

clinical trial drug supply and agreement on the trial design from the

FDA and foreign regulatory authorities. An update will be provided as

soon as additional information is available.

-- Nominating a lead product candidate from a new series of potent anti

HCV molecules for IND or foreign regulatory equivalent filing and

first-in-human clinical trials.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharma
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
2. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
3. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
4. Pharmassets Underwriters Release Shares from Lock-Up
5. Nephros Reports 2008 First Quarter Financial Results
6. PreMD Reports First Quarter Results
7. Lifeway Foods Reports Record 1st Quarter 2008 Results
8. Corgenix Reports Third Quarter Fiscal 2008 Financial Results
9. Tiens Biotech Group (USA) Reports First Quarter Results
10. Cardiogenesis Reports First Quarter 2008 Results
11. STEN Corp. Reports 2008 Second-Quarter Revenue of $4.3 Million and Improved Results From Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2015)... , ... July 05, 2015 , ... Women’s Excellence ... college) at their Lake Orion location. The special consists of 2 months of unlimited ... Wellness, powered by Movestrong is located at 1410 South Lapeer Road in Lake Orion. ...
(Date:7/4/2015)... (PRWEB) , ... July 04, 2015 , ... ... Plastic Surgeons published the results of an annual member survey , detailing ... United States. More recently, the group broke that raw data down into charts ...
(Date:7/4/2015)... ... July 04, 2015 , ... Tyler Boden, Project Developer of ... expertise from the North American Board of Certified Energy Practitioners (NABCEP®), and is ... respected and well established national certification organization for renewable energy professionals. Designation as ...
(Date:7/3/2015)... ... , ... On June 30th SEO authority and veteran Internet ... "Page One Engine" . The program, which has been hailed as the ... well-known marketers. HonestyFirstReviews.com's Tiffany Hendricks has joined the party, publishing an in-depth review ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Renowned rhinoplasty ... dates for the 2016 Dallas Rhinoplasty Symposium . To be held from March ... meeting will be held at the Westin Galleria Dallas. , Designed to take participants ...
Breaking Medicine News(10 mins):Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3
... earthquake to ravage China in decades, the task of ... onerous one. The 7.9-magnitude earthquake of 12 May devastated ... and causing extensive property damage. , Among the many ... enemy stray radioactive sources that could complicate relief ...
... 2008: Low bone mineral density in the hand is ... rheumatoid arthritis (RA) and indicates long-term prognosis, according to ... Annual Congress of the European League Against Rheumatism in ... density to be as effective predicting mortality as well-established ...
... France June 12, 2008 -- Biogen Idec ... the first dual-mechanism, lymphotoxin-; (LT-;) and LIGHT pathway ... diseases, including rheumatoid arthritis (RA), during the 2008 ... of Rheumatology at the Le Palais de Congrs ...
... Sales Already Exceed Q1 2008 and Q2 2007 Levels, - ... ... Surgeons, MONROVIA, Calif., June 12 STAAR ... invasive ophthalmic products, today announced that Visian ICL(TM),(Implantable Collamer Lens) sales in ...
... Laurent Claret Will Present Case Studies on the ... and Survival Benefits of Anticancer Agents, MOUNTAIN ... PHST ), a leading provider of software, strategic,consulting, ... announced that Laurent Claret, Ph.D., senior scientist,Pharsight Strategic ...
... A research abstract that will be presented on ... the Associated Professional Sleep Societies (APSS), finds a link ... adolescents with depressive episodes. , The study, authored by ... Brazil, focused on 303 individuals with pediatric bipolar disorder ...
Cached Medicine News:Health News:In quake's aftermath, Chinese sift through rubble for radioactivity 2Health News:Hand bone mineral density is an effective predictor of mortality in rheumatoid arthritis 2Health News:Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis 2Health News:Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis 3Health News:Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis 4Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 2Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 3Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 4Health News:Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting 2Health News:Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting 3Health News:Poor sleep linked to suicidal behavior among children and adolescents with depressive episodes 2Health News:Poor sleep linked to suicidal behavior among children and adolescents with depressive episodes 3
(Date:7/6/2015)... and SOUTH SAN FRANCISCO, Calif. ... (NYSE: AGN ), a leading global pharmaceutical company, ... developing novel treatments for dry eye disease, today announced ... Allergan will acquire Oculeve in an all-cash transaction.  Under ... for a $125 million upfront payment and commercialization milestone ...
(Date:7/6/2015)... July 6, 2015 /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. ... leading retail drugstore chain in China ... today announced that its board of directors has received ... from Simin Zhang , chairman of the board ... Holding Ltd., an investment vehicle wholly owned by Mr. ...
(Date:7/4/2015)... July 4, 2015 Adding ... patients with unresectable metastatic colorectal cancer in the ... organ Patients with unresectable metastatic colorectal ... liver experienced the greatest improvement in Progression-Free Survival ... SIR-Spheres Y-90 resin microspheres to a current first-line ...
Breaking Medicine Technology:Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4
... March 16 Healthpoint today announced that it has ... of HP802-247 in venous leg ulcers. HP802-247 is a ... is designed to determine the effectiveness of two cell ... with standard care, compared to placebo plus standard care, ...
... Aims To Enhance Precision and Reduce High Failure ... Hamilton, N.J., March 16 ICON (Nasdaq: ... outsourced development services to the pharmaceutical, biotechnology and ... in centralized psychiatric patient evaluation, today announced that ...
Cached Medicine Technology:Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 2Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 3ICON and MedAvante Sign Alliance Agreement 2
... OMNISCAN was launched in the U.S. in ... central nervous system (CNS) to detect lesions ... tissues. OMNISCAN has since received approval for ... pediatric CNS and body indications. OMNISCAN comes ...
... ferumoxides) is Advanced Magnetics' contrast agent for use ... It is the first organ-specific MRI contrast agent ... function, the agent is taken up by macrophages ... in most tumors. The liver is a principal ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
... only isosmolar contrast medium (IOCM) available in the ... blood, VISIPAQUE was designed for patient safety and ... formulated with sodium and calcium in a ratio ... approval for use in children over one year ...
Medicine Products: